Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$940MCash, Jun 2026
25moCash Runway (est.)
+9%Share Count, 1 Year
Follow DNLI by emailGet an email when DNLI pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about DNLI, unsubscribe in one click. Privacy
📣 What DNLI Says Is Next
first half of 2027 · “Data from BEACON are expected in the first half of 2027.”
Company press release, Aug 6, 2026 · SEC filing
in 2027 · “Safety and clinical proof-of-concept data from the ongoing Phase 1/1b study of DNL921 in healthy volunteers and participants with Alzheimer's disease are expected in 2027.”
Company press release, Aug 6, 2026 · SEC filing
first half of 2027 · “Initial clinical biomarker data from the ongoing Phase 1b study of DNL628 in participants with Alzheimer’s disease are expected in the first half of 2027. 2 DNL921 (ATV:Abeta) for Alzheimer's disease DNL921 is an investigational Antibody TransportVehicle ™ (ATV)-enabled antibody designed for systemic delivery across the blood-brain barrier to target amyloid plaques in Alzheimer's disease.”
Company press release, Aug 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
DNLI reported $940M in cash and short-term investments (as of Jun 30, 2026) and used about $115M/quarter in operations, an estimated runway of 24.5 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DNLI and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.